Molecular Hydrogen and Dementia Prevention: Czech Research Heads into Its First Clinical Study
Today, on 12 November 2025, a press conference of H2 Medical Technologies, part of the H2 Global Group, was held at the ČTK Press Centre, where we announced a major milestone – the approval of the first clinical study by SÚKL in the Czech Republic focused on the inhalation of molecular hydrogen in patients with mild cognitive impairment (MCI).
Mild cognitive impairment is a condition that often precedes Alzheimer’s dementia. The possibility of early intervention at this stage is crucial – and this is precisely where molecular hydrogen may play an important role. The study was also approved by the Ethics Committee of the University Hospital Ostrava, where it will be conducted.
You can find the full ČTK article and the press conference recording here:
České noviny
https://www.ceskenoviny.cz/zpravy/2745785
Hospodářské noviny
https://domaci.hn.cz/c1-67811780-zive-molekularni-vodik-pro-prevenci-i-lecbu-kognitivnich-poruch
How will the study be conducted?
The approved clinical study is designed to evaluate as precisely as possible the safety and potential benefits of inhaling molecular hydrogen in patients with cognitive impairment.
Basic study parameters:
-
Start: January 2026
-
Duration: 6 months
-
Number of participants: approx. 30 patients
-
Age range: 50–80 years
Study procedure:
-
inhalation of molecular hydrogen for 1 hour per day,
-
5× per week for 3 months,
-
followed by a 3-month monitoring phase without active intervention.
The study will track:
-
safety of molecular hydrogen inhalation,
-
changes in biochemical markers,
-
impact on cognitive functions,
-
and quality of life from the patients’ perspective.
Building on Japanese research and a European patent
This clinical study builds on the work of Professor Shigeo Ohta in Japan, one of the co-founders of H2 Global Group. His research led to the granting of the European patent EP3701956B1, covering the prophylaxis and treatment of dementia using molecular hydrogen.
Thanks to this patent, our development is based on a strong scientific and intellectual-property foundation, which enhances:
-
the credibility of the technology,
-
our position in the field of innovative therapeutic approaches,
-
and the future potential for global application.
Czech innovation with global impact
Approval of the clinical study is an important step towards our goal:
to introduce, in 2026, the world’s first medical device using molecular hydrogen, developed in the Czech Republic.
We then plan to expand it to other EU countries, the USA, and Asia. This milestone:
-
strengthens our scientific credibility,
-
reinforces our regulatory standing,
-
and confirms that Czech know-how can play a role in global medicine, particularly in the field of neurodegenerative diseases such as Alzheimer’s dementia.
We are seeking volunteers for the clinical study
As part of today’s announcement, we are also calling for volunteers who wish to actively participate in the research and contribute to improving future options for the prevention and treatment of dementia.
Who are we looking for?
-
individuals aged 50–80,
-
in generally good health,
-
diagnosed with mild cognitive impairment or mild to moderate dementia,
-
ideally from Ostrava and the surrounding area (the study is conducted at University Hospital Ostrava).
How to apply?
Interested participants can apply until 30 November 2025 at:
📧 david.skoloudik@H2medical.com
Our thanks and our vision
This step would not have been possible without the support of our partners, experts, and investors who believe that molecular hydrogen can become a new, safe, and non-invasive tool in combating the devastating effects of dementia.
Thank you to everyone who supports us on this journey and helps us develop Czech innovation with global reach.